ADVIL MIGRAINE LIQUI-GELS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVIL MIGRAINE LIQUI-GELS (ADVIL MIGRAINE LIQUI-GELS).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever.
| Metabolism | Primarily hepatic metabolism via CYP2C9 and to a lesser extent CYP2C8; undergoes glucuronidation and renal excretion of metabolites and unchanged drug. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for approximately 90% of an administered dose, with about 10% excreted in feces via bile. Less than 1% is excreted unchanged in urine; the remainder as conjugates and oxidative metabolites. |
| Half-life | Terminal elimination half-life is approximately 2 hours (range 1.8–3.5 hours). In clinical context, this short half-life supports dosing every 4–6 hours for acute migraine treatment, but drug effects may persist beyond this due to slow dissociation from COX enzymes. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is about 0.1–0.2 L/kg. This low Vd indicates limited tissue distribution and high plasma protein binding, with drug mainly confined to the vascular compartment. |
| Bioavailability | Oral bioavailability is approximately 80–100% for ibuprofen immediate-release formulations, including Liqui-Gels. Food may slightly delay absorption but does not significantly reduce total absorption. |
| Onset of Action | Oral (Liqui-Gels): Onset of analgesia occurs within 30–60 minutes. For migraine, significant headache relief may be observed within 1–2 hours. |
| Duration of Action | Duration of analgesic effect is 4–6 hours. Clinical notes: In migraine, the duration of headache relief may extend up to 8 hours in some patients, but repeated dosing is often required for complete resolution. |
400 mg (two 200 mg Liqui-Gels) orally every 6 to 8 hours as needed; maximum 1200 mg per day.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 30-60 mL/min: use minimum effective dose, avoid if possible. eGFR <30 mL/min or dialysis: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: use with caution, reduce dose. Child-Pugh C: contraindicated. |
| Pediatric use | ≥12 years: same as adult. <12 years: not recommended. |
| Geriatric use | Use lowest effective dose for shortest duration; monitor renal function, GI bleeding risk, and drug interactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADVIL MIGRAINE LIQUI-GELS (ADVIL MIGRAINE LIQUI-GELS).
| Breastfeeding | Ibuprofen transfers into breast milk in low amounts (M/P ratio ~0.01–0.05); considered compatible with breastfeeding due to low infant dose (<0.1% of maternal weight-adjusted dose). |
| Teratogenic Risk | First trimester: Case-control studies suggest small increased risk of miscarriage and cardiac defects; avoid use. Second/Third trimester: Associated with premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis; contraindicated after 30 weeks gestation. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are also contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
["History of allergic reaction to ibuprofen, aspirin, or other NSAIDs","Active peptic ulcer disease or gastrointestinal bleeding","Severe heart failure (NYHA class III-IV)","Peri-operative pain in CABG surgery","Third trimester of pregnancy (risk of premature closure of ductus arteriosus)","Severe renal impairment (CrCl <30 mL/min) or advanced renal disease","Severe hepatic impairment"]
| Precautions | ["Cardiovascular thrombotic events (MI, stroke)","Gastrointestinal adverse events (bleeding, ulceration, perforation)","Hypertension","Heart failure and edema","Renal toxicity (including acute renal failure) in patients with impaired renal function","Anaphylactoid reactions","Exacerbation of asthma","Serious skin reactions (e.g., Stevens-Johnson syndrome)","Hepatic toxicity","Hematologic toxicity (e.g., inhibition of platelet aggregation)","Use with caution in elderly patients and those with prior GI disease"] |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal ductus arteriosus and amniotic fluid volume via ultrasound if used in third trimester; monitor maternal renal function, bleeding time, and gastrointestinal symptoms. |
| Fertility Effects | Reversible inhibition of ovulation and luteal phase defects via prostaglandin synthesis inhibition; may delay time to conception; effect resolves upon discontinuation. |
| Food/Dietary | Avoid alcohol; may increase risk of gastrointestinal bleeding. Take with food or milk to minimize GI irritation. Avoid high-caffeine beverages (coffee, tea, soda) as this product contains caffeine and may cause overstimulation. |
| Clinical Pearls | Advil Migraine Liqui-Gels contain ibuprofen 200 mg and caffeine 150 mg. The caffeine enhances analgesia and vasoconstriction. Use cautiously in patients with hypertension, anxiety, or peptic ulcer disease. Onset of action is faster due to liquid-filled capsule. Maximum single dose is 2 capsules; do not exceed 2 capsules in 24 hours unless directed by a physician. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not take more than 2 capsules in 24 hours. · Avoid alcohol while taking this medication. · Stop use and consult a doctor if migraine persists or worsens. · Do not use if you have ever had an allergic reaction to ibuprofen or aspirin. |